Drug trafficking continues to be one of the most complex and consequential financial crime threats facing financial institutions in the United States today. The flow of drugs and scale of illicit proceeds, the sophistication of transnational criminal networks and an intensifying inter-agency response posture have made it clear that conventional approaches to detection are no longer sufficient.
Recently, I spoke with Rini Joseph, Targeted Typologies Product Manager at Nasdaq Verafin about what effective drug trafficking detection requires. Our conversation explored how financial institutions should think about this evolving typology and what it takes to detect drug trafficking activity with greater precision.
Why Does Drug Trafficking Require a Different Detection Approach?
Drug trafficking is fundamentally different from many other forms of financial crime — highly organized, network-driven and constantly evolving. It is not usually defined by a single suspicious transaction or threshold breach. It is more often revealed through patterns of behavior that only become clear when activity is viewed in context.
According to Rini, that’s exactly what conventional approaches miss. “Traditional AML monitoring programs were designed to identify broad suspicious activity, often relying on rule-based scenarios that generate large volumes of alerts,” she said. “That approach can identify unusual behavior, but it is not always designed to detect specific predicate offences like drug trafficking, where activity is deliberately structured to appear ordinary when viewed in isolation.”
Drug trafficking is also an organized crime and national security issue. It is frequently tied to transnational criminal organizations that understand money laundering techniques extremely well. “Detecting that activity requires a more intentional approach — one that is purpose-built to identify drug trafficking behaviors rather than hoping they surface through general monitoring,” Rini said.
Where do Legacy AML Systems Fall Short?
Legacy monitoring systems tend to focus on identifying suspicious transactions without giving investigators the broader context they need to understand why those transactions matter.
As Rini noted, that leaves AML teams working with fragments of information. “They may see individual alerts that suggest something is wrong, but not enough evidence to confidently identify a specific typology like drug trafficking. In practice, this means investigators can see transactional red flags but may not have the behavioral context needed to build a coherent narrative.”
“That gap creates two problems. First, it increases investigative burden because teams must manually piece together information across different systems and sources. Second, it limits effectiveness because high alert volumes can obscure the most serious risks. Instead of helping investigators clearly identify drug trafficking activity, legacy approaches can make it harder to separate meaningful signals from noise.”
How is the Inter-Agency Response Posture Intensifying?
Government agencies have been clear that drug trafficking is a priority risk area. It is included in FinCEN’s National AML/CFT Priorities and identified as a top threat in the 2026 National Money Laundering Risk Assessment. Rini and I agreed that the shift is not only about what institutions should focus on. It is also about how they demonstrate effectiveness.
“Financial institutions are increasingly being asked to provide clear, well-supported intelligence,” Rini said. “That means moving beyond the simple identification of suspicious activity and toward explaining why activity is suspicious, how it aligns to a specific typology and what evidence supports that conclusion.”
For AML programs, that distinction matters. High volumes of generic alerts are no longer enough and, in many cases, they create unnecessary operational strain. What is more valuable is fewer, richer alerts that are easier to investigate, more defensible and more useful to law enforcement.
What Does Effective Drug Trafficking Detection Look Like in Practice?
Effective drug trafficking detection needs to be targeted, contextual and intelligence-driven. Rather than relying on a single indicator, it should bring together multiple dimensions of risk to identify activity that aligns with known drug trafficking behaviors.
That includes analyzing transactional patterns such as high cash usage or P2P activity, alongside behavioral indicators like frequent travel, hotel stays, late-night ATM deposits or financial activity that does not align with known income sources. “Any one of those signals may not be enough on its own. But when they are connected, patterns can emerge that would not be visible through traditional monitoring alone,” said Rini.
“Technology also plays an important role. Advanced analytics and AI can help surface relevant negative news and external intelligence directly within the detection process. That reduces manual research, strengthens investigative outcomes and helps investigators understand the full story faster.”
The goal is not to generate more alerts. The goal is to produce low-volume, high-quality alerts that already contain the context investigators need to move forward with confidence.
What Should Institutions Look for as they Prioritize Drug Trafficking Detection?
Drug trafficking is a sophisticated and fast-moving typology. The actors involved continuously adapt their methods to avoid detection, so financial institutions need to think carefully about how they evaluate detection capabilities.
Effective solutions should take a targeted approach. As Rini noted, “they should focus specifically on drug trafficking behaviors rather than broad indicators of suspicious activity. They should combine multiple data sources — including transactional, behavioral and external intelligence — and use technologies like AI to improve both effectiveness and efficiency.”
“Most importantly, institutions should prioritize targeted typology approaches. The ability to clearly explain why activity appears to be connected to drug trafficking, supported by relevant data points, is critical for meeting regulatory expectations and supporting law enforcement outcomes,” she said.
In an environment where illicit actors are increasingly sophisticated, detection strategies need to be equally advanced. Complex problems require equally sophisticated solutions.
From Monitoring to Targeted Detection: My Takeaways
If one theme stands out from this conversation, it is that drug trafficking detection is not about adding more volume to already overwhelmed AML teams. It is about improving precision.
Drug trafficking presents one of the greatest challenges facing modern AML programs, but it also highlights the limitations of traditional approaches. As criminal networks evolve and regulatory expectations rise, effectiveness depends on moving beyond generic monitoring toward targeted, contextual detection.
By focusing on intelligence rather than volume, financial institutions can reduce operational burden, improve investigative outcomes and play a more meaningful role in disrupting drug trafficking networks.
About the Experts
Fouad Hassouneh, VP, Head of New Products Strategy, Nasdaq Verafin
Since joining Nasdaq Verafin in 2013, Fouad has excelled in a wide range of roles. In his current role as VP, Head of New Products Strategy, Fouad is responsible for defining the product vision, strategy and roadmap. He helps Nasdaq Verafin deliver solutions that leverage artificial intelligence to effectively detect money laundering, while helping institutions maintain compliance. Working in close collaboration with Nasdaq Verafin colleagues, customers and senior stakeholders, Fouad applies his extensive knowledge of the AML/CFT and fraud landscapes to guide innovations and enhancements to product management and analytics. Fouad is passionate about creating value for customers and society by combating financial crime with cutting-edge technology.
Rini Joseph, Targeted Typologies Product Manager, Nasdaq Verafin
With over 18 years of experience spanning software engineering, professional services and product management, Rini is a results-driven product manager passionate about delivering measurable value to customers.
Rini’s professional foundation in software engineering and computer science combined with a wealth of product management experience has equipped her with the analytical mindset and technical expertise needed to tackle complex, real-world problems effectively.
In her current role as Product Manager for Targeted Typologies at Nasdaq Verafin, Rini is dedicated to building solutions that combat financial crime through innovative cutting-edge technology, supported by informed research and industry expertise.
